RasimAGucalpMD

Oncology • Bronx, NY

Professor, Medicine, Oncology, Albert Einstein College of Medicine

Join to view full profile

Dr. Gucalp is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gucalp's full profile

Already have an account?

Office
111 E 210th St
Bronx, NY 10467
Phone+1 718-405-8536

Fax+1 718-798-7474
Is this information wrong?

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1986 - 1990
SUNY Health Science Center at BrooklynResidency, Internal Medicine, 1982 - 1984
Hacettepe University FOMClass of 1975

Certifications & Licensure

NY State Medical License 1992 - 2024
TX State Medical License 1992 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Start of enrollment: 1988 Apr 01
Completed
Phase 2
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2002 Jan 01
Unknown status
Phase 2
Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer Start of enrollment: 2004 May 01
Terminated
Phase 2
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2015 Feb 09
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
HIV Associated Lung Cancer: Unique Clinicopathologic Features and Immune Biomarkers Impacting Lung Cancer Screening and Management.
Ayse Ece Cali Daylan, Catarina Martins Maia, Shirin Attarian, Xiaoling Guo, Mindy Ginsberg, Enrico Castellucci, Rasim Gucalp, Missak Haigentz, Balazs Halmos, Haiying C...> ;Clinical Lung Cancer. 2024 Mar 1
1 citations
Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT).
Nitin Ohri, Shruti Jolly, Benjamin T Cooper, Rafi Kabarriti, William R Bodner, Jonathan Klein, Chandan Guha, Shankar Viswanathan, Elaine Shum, Joshua K Sabari, Haiying...> ;Journal of Clinical Oncology. 2024 Feb 10
1 citations
Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer.
Michael Pennock, Balazs Halmos, William Bodner, Haiying Cheng, Rasim Gucalp, Nitin Ohri> ;Clinical and Translational Radiation Oncology. 2023 Jul 1
9 citations
Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort.
Angelica D'Aiello, Juan Lin, Rasim Gucalp, Vafa Tabatabaie, Haiying Cheng, Noah A Bloomgarden, Yaron Tomer, Balazs Halmos> ;Cancers. 2021 Mar 23
8 citations
First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
Haiying Cheng, Yiyu Zou, Chirag D. Shah, Ni Fan, Tushar D. Bhagat, Rasim Gucalp, Mimi Y. Kim, Amit Verma, Bilal Piperdi, Simon D. Spivack, Balazs Halmos, Roman Perez-S...> ;Lung Cancer. 2021 Apr 1
12 citations
Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis
Nitin Ohri, Balazs Halmos, William Bodner, Haiying Cheng, Madhur Garg, Rasim Gucalp, Chandan Guha> ;Practical Radiation Oncology. 2021 Mar 1
42 citations
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Maximilian Hochmair, Alessandro Morabito, D. Hao, Cheng-Ta Yang, Ross A. Soo, James Chih-Hsin Yang, Rasim Gucalp, Balazs Halmos, Angela Märten, Tanja Cufer> ;Future Oncology. 2020 Aug 28
5 citations
Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis.
Bruce Feinberg, Balazs Halmos, Rasim Gucalp, Wenbo Tang, Barbara Moehring, Maximillian J Hochmair> ;Future Oncology. 2020 Aug 6
21 citations
Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma.
Vineeth Sukrithan, Jason E. Sandler, Rasim Gucalp, Richard J. Gralla, Balazs Halmos> ;Clinical Lung Cancer. 2019 May 1
7 citations
Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved Community.
Christopher Su, Vincent Chau, Balazs Halmos, Chirag D. Shah, Rasim Gucalp, Stuart H. Packer, Kevin Wilson, Bruce D. Rapkin, Roman Perez-Soler, Haiying Cheng> ;American Journal of Clinical Oncology. 2019 Mar 1
65 citations
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
Maximilian Hochmair, Alessandro Morabito, D. Hao, Cheng-Ta Yang, Ross A. Soo, James Chih-Hsin Yang, Rasim Gucalp, Balazs Halmos, L. Wang, Angela Märten, Tanja Cufer> ;Future Oncology. 2019 Aug 2
82 citations
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Maximilian Hochmair, Alessandro Morabito, D. Hao, Cheng-Ta Yang, Ross A. Soo, James Chih-Hsin Yang, Rasim Gucalp, Balazs Halmos, L. Wang, Amanda K. Golembesky, Angela ...> ;Future Oncology. 2018 Oct 19
9 citations
Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community.
Christopher Su, Amit Bhargava, Chirag D. Shah, Balazs Halmos, Rasim Gucalp, Stuart H. Packer, Nitin Ohri, Linda B. Haramati, Roman Perez-Soler, Haiying Cheng> ;Clinical Lung Cancer. 2018 Sep 1
4 citations
Secondhand Smoke Exposure Among Community-Dwelling Adult Cancer Survivors in the United States: 1999-2012.
Oladimeji Akinboro, Odunayo Olorunfemi, Prasanta Basak, Elizabeth J. Phillips, Daniel Pomerantz, Bernard Bernhardt, Rasim Gucalp, Stephen Jesmajian, Jamie S. Ostroff> ;Cancer Epidemiology, Biomarkers & Prevention. 2017 Aug 1
11 citations
Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Nitin Ohri, William Bodner, Rafi Kabarriti, Viswanathan Shankar, Haiying Cheng, Tony Abraham, Balazs Halmos, Rasim Gucalp, Roman Perez-Soler, Shalom Kalnicki, Madhur Garg> ;International Journal of Radiation Oncology, Biology, Physics. 2017 Jan 1
6 citations
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung C...
Tianhong Li, Bilal Piperdi, William V. Walsh, Mimi Kim, Laurel A. Beckett, Rasim Gucalp, Missak Haigentz, Venu Bathini, Huiyu Wen, Kaili Zhou, Patricia Pasquinelli, Sr...> ;Clinical Lung Cancer. 2017 Jan 1
17 citations
Evolving Concepts: Immunity in Oncology from Targets to Treatments.
Hina Khan, Rasim Gucalp, Iuliana Shapira> ;Journal of Oncology. 2015 Apr 28
20 citations
Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Nitin Ohri, Bilal Piperdi, Madhur Garg, William Bodner, Rasim Gucalp, Roman Perez-Soler, Steven M. Keller, Chandan Guha> ;Lung Cancer. 2015 Jan 1
91 citations
Denosumab for treatment of hypercalcemia of malignancy.
Mimi I. Hu, Ilya G. Glezerman, Sophie Leboulleux, Karl L. Insogna, Rasim Gucalp, Waldemar Misiorowski, Bennett Yu, Paul Zorsky, Diego Tosi, Alberto Bessudo, Arnaud Jac...> ;The Journal of Clinical Endocrinology and Metabolism. 2014 Jun 10
25 citations
Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment
Mimi I. Hu, Ilya G. Glezerman, Sophie Leboulleux, Karl L. Insogna, Rasim Gucalp, Waldemar Misiorowski, Bennett Yu, Wendy Ying, Rajul K. Jain> ;Journal of the National Cancer Institute. 2013 Sep 18
A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates.
Hu MI, Gucalp R, Insogna KL, Glezerman I, Bone HG, Jaccard A, Misiorowski W, Yu BW, Yeh H> ;J. Clin. Oncol.. 2011-05-20
45 citations
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Tianhong Li, Liawaty Ho, Bilal Piperdi, Tarek N. Elrafei, Fernando Camacho, James R. Rigas, Roman Perez-Soler, Rasim Gucalp> ;Lung Cancer. 2010 Apr 1
2 citations
Inferior vena cava syndrome from pancreatic adenocarcinoma: successful symptom palliation with endovascular stenting.
Stuart Akerman, Andreas Kaubisch, Rasim Gucalp, Larry Scher, Missak Haigentz> ;Journal of Palliative Medicine. 2008 Nov 3
Phase II study to evaluate the efficacy and safety of bortezomib (PS-341) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Ho L, Li T, Piperdi B, Macapinlac M, Rigas JR, Camacho F, Perez-Soler R, Gucalp R> ;J. Clin. Oncol.. 2008-05-20
Lung cancer in HIV infection: A case series.
Jung G, Chung J, Shuter J, Gucalp R, Perez-Soler R, Keller S, Haigentz M> ;J. Clin. Oncol.. 2008-05-20
Join now to see all